ViyaSH Scientific Ltd - unit to buy 100% shareholding of Bioforlife Italia

Viyash Scientific Ltd., an integrated pharmaceutical enterprise with operations spanning active pharmaceutical ingredients (API), human health, animal health, and contract development and manufacturing organization (CDMO) services, has announced plans to acquire 100% of the shareholding in Bioforlife Italia. The move is part of the company’s broader strategy to expand its global footprint and strengthen its position in the pharmaceutical sector.

Bioforlife Italia, based in Italy, is known for its expertise in niche formulations and advanced pharmaceutical technologies. The acquisition is expected to enhance Viyash’s capabilities in R&D and manufacturing, particularly in the European market. With a team of over 200 scientists and nine USFDA-approved manufacturing facilities, Viyash is well-positioned to integrate Bioforlife Italia’s operations into its existing infrastructure.

The transaction is subject to regulatory approvals and is expected to be finalized in the coming months. The acquisition aligns with Viyash’s ongoing consolidation efforts, including its recent merger with SeQuent Scientific, which was designed to create a leading platform in the animal healthcare segment.

Financial details of the deal have not been disclosed. However, the acquisition is expected to be funded through a combination of internal resources and existing capital structures. Analysts suggest that the move could lead to expanded market access and enhanced R&D capabilities.

The acquisition of Bioforlife Italia reflects Viyash’s commitment to strategic growth and global expansion, particularly in high-value pharmaceutical segments. As the company continues to consolidate its portfolio, stakeholders will be watching closely for signs of improved operational efficiency and shareholder value creation.